Antiangiogenic Agents in the Treatment of Recurrent or Newly Diagnosed Glioblastoma: Analysis of Single-Agent and Combined Modality Approaches

Radiation Oncology - United Kingdom
doi 10.1186/1748-717x-6-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2013English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Using Temozolomide in Newly Diagnosed Glioblastoma Multiforme – A Single-Centre Experience

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2010English

Cytotoxic Chemotherapeutic Management of Newly Diagnosed Glioblastoma Multiforme

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2009English

Prognostic Value of the S100B Protein in Newly Diagnosed and Recurrent Glioma Patients: A Serial Analysis

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2016English

Conservative Treatment of Newly Diagnosed Keratoconus

Acta Ophthalmologica
MedicineOphthalmology
2018English

Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

Radiotherapy and Oncology
Nuclear MedicineOncologyRadiologyHematologyImaging
2009English

A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Combined Modality Treatment of Anal Carcinoma

Oncologist
Cancer ResearchMedicineOncology
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy